Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Concord Biotech
Mid Cap•1,571 Employees•IPO 2023
Current Price
₹1207.20
3.5 (0.29%)Updated
Today's Range
₹1188.60
₹1214.00
₹1207.20
52 Week Range
52W Low₹1068.60
52W High₹2150.40
₹1207.20
Downside12.97%
Upside78.13%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹11,978.03 Cr
Market Cap
Total market value of companyP/E Ratio
37.73
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
9.43
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹30.89
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
11.18%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
28.20%
ROCE
Return on Capital Employed. >15% is goodNet Margin
28.75%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
17.05%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
18.56%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-5.47%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-26.10%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
-
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹173.27
Book Value
Net asset value per shareDividend Yield
0.92%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
44.10%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Concord Biotech demonstrates strong capital efficiency with a robust Return on Equity (ROE) of 21.30% and an impressive Return on Capital Employed (ROCE) of 28.20%. These figures highlight the company's effective utilization of shareholder funds and overall operational profitability.
- •The company maintains an exceptionally high Operating Profit Margin (OPM) of 40.60%, indicating strong pricing power and highly efficient cost management. This robust margin contributes significantly to its overall profitability and financial stability.
Weaknesses
4 points- •The stock has experienced significant volatility, with its 52-week high at ₹2451.70 and low at ₹1345.00. This wide price range indicates potential instability, which could be a concern for investors seeking more predictable returns.
- •The company reported a notable decline in recent quarterly profit, with a -26.10% variation in PAT. This significant drop in short-term profitability warrants close monitoring to understand underlying causes and potential impacts on future earnings.
Opportunities
3 points- •The global pharmaceuticals industry is poised for sustained growth, driven by an aging population, rising healthcare expenditure, and increasing prevalence of chronic diseases, offering Concord Biotech significant market expansion opportunities.
- •Continuous investment in research and development (R&D) for new drug discovery and product diversification can open new revenue streams and market segments. This strategic focus could enhance Concord Biotech's competitive edge.
Threats
4 points- •The pharmaceutical sector is highly competitive, with numerous established players and new entrants. Intense competition from peers like Sun Pharma and Cipla could exert pressure on Concord Biotech's market share and pricing power.
- •Stringent and evolving regulatory landscapes, including drug approval processes, pricing controls, and manufacturing standards, pose a continuous threat. Non-compliance or adverse changes could significantly impact operations and profitability.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1268.73 | +₹61.53 | +5.10% |
| R3 | ₹1243.33 | +₹36.13 | +2.99% |
| R2 | ₹1228.67 | +₹21.47 | +1.78% |
| R1 | ₹1217.93 | +₹10.73 | +0.89% |
| PIVOT | ₹1203.27 | -3.93 | -0.33% |
| CURRENT | ₹1207.20 | - | - |
| S1 | ₹1141.73 | -₹65.47 | -5.42% |
| S2 | ₹1167.13 | -₹40.07 | -3.32% |
| S3 | ₹1177.87 | -₹29.33 | -2.43% |
| S4 | ₹1192.53 | -₹14.67 | -1.21% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-95.7% vs avg
0.49L
(06 Mar 2026)Delivery %+12.6% vs avg
42.9%
(06 Mar 2026)Avg Volume (20D)20-day average
1.15M
(06 Feb - 06 Mar)Avg Delivery %Trend ↑
30.3%
(06 Feb - 06 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Procter & Gamble Health Ltd
158.00 %
Highest Dividend Yield
Procter & Gamble Health Ltd
3.64 %
Peer Comparison
| Company Name |
|---|
 Acutaas Chemicals Ltd |
 Aether Industries Ltd |
 Alivus Life Sciences Ltd |
 Alembic Pharmaceuticals Ltd |
 Caplin Point Laboratories Ltd |
 Cohance Lifesciences Ltd |
 ERIS Lifesciences Ltd |
 Granules India Ltd |
 Jubilant Pharmova Ltd |
 Natco Pharma Ltd |
 Neuland Laboratories Ltd |
 Procter & Gamble Health Ltd |
 |
 Sanofi India Ltd |
 Sanofi Consumer Healthcare India Ltd |
 Sun Pharmaceutical Industries Ltd |
 Wockhardt Ltd |
About
Concord Biotech Ltd
Concord Biotech Limited is an Indian biopharmaceutical company specializing in the research, development, manufacturing, and sale of pharmaceutical products both domestically and internationally. Their core competency lies in fermentation-based Active Pharmaceutical Ingredients (APIs), which are essential components in various medications.
The company's product portfolio is diverse and spans several therapeutic areas. In immunosuppressants, they offer a range of key APIs including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus. Their oncology segment features APIs such as temsirolimus, everolimus, romidepsin, and several others used in cancer treatments. Concord Biotech also manufactures APIs for antibacterial applications, including mupirocin, polymyxin B sulfate, and fidaxomicin, and for antifungal treatments, offering anidulafungin, caspofungi, and more.
Beyond their own branded APIs, Concord Biotech provides contract research and manufacturing services (CRAMS) focused on fermentation and semi-synthesis products. This business model allows them to leverage their expertise in fermentation processes to offer services to other pharmaceutical companies, contributing to their revenue streams and expanding their reach within the industry.
Established in 1984 and headquartered in Ahmedabad, India, Concord Biotech has a long history in the pharmaceutical sector. Their focus on fermentation-based APIs, combined with their CRAMS services, positions them as a significant player in the global biopharmaceutical market, catering to a wide range of therapeutic needs and client demands. The company's continued success relies on their ability to innovate, maintain high manufacturing standards, and effectively navigate the complexities of the global pharmaceutical landscape.
COMPANY FACTS - CONCORDBIO
Registered Address
16th Floor, B-Wing, Mondeal Heights,, Iscon Cross Road, S.G. Highway,
Ahmedabad
GUJARAT
IN
Tel: 917968138700
Website:https://www.concordbiotech.com/
Investor Relations:https://www.concordbiotech.com/investors/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,571
IPO Date: 18/08/2023
MANAGEMENT - CONCORDBIO
Mr. Sudhir Vaid
Executive Chairman of the Board, Managing Director
Mr. Ankur Vaid
Chief Executive Officer, Joint Managing Director, Executive Director
Mr. Lalit Sethi
Chief Financial Officer
Ms. Hina Patel
Company Secretary and Compliance Officer
Mr. Devang Bhatt
Vice President - Sales and Marketing, Head - Limbasi Plant - 3
Dr. Manoj Kumar
Vice-President - Formulation Division and Head - Valthera Unit - 2
Mr. Sundeep Bengani
General Manager - International Business Development, Formulation Division
Mr. Rajiv Agarwal
Non-Executive Nominee Director
Mr. Ravi Kapoor
Non-Executive Director
Shri. Arvind Agarwal
Non-Executive Independent Director
Mr. Jayaram Easwaran
Non-Executive Independent Director
Mrs. Bharti Khanna
Non-Executive Independent Director
Investor Questions Answered
Concord Biotech Ltd (CONCORDBIO) Stock FAQs
Get answers to the most common questions about Concord Biotech Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Concord Biotech Ltd (CONCORDBIO) is ₹1,207.2. Today, the stock has gained by ₹3.50 (0.29%), trading in a range of ₹1,188.6 to ₹1,214. The stock opened at ₹1,203.7 with a trading volume of 48,879 shares.
Concord Biotech Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹11,978.03 crores, P/E ratio of 37.73, ROE of 11.18%, and ROCE of 28.20%. The dividend yield stands at 0.92%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Concord Biotech Ltd (CONCORDBIO) is ₹2,150.4, while the 52-week low is ₹1,068.6. Currently trading at ₹1,207.2, the stock is 12.8% away from its 52-week low and 43.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Concord Biotech Ltd stock at ₹1,207.2 depends on multiple factors. The stock is currently trading with a P/E ratio of 37.73 and P/B ratio of N/A. Today's performance shows a gain of 0.29%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Concord Biotech Ltd offers a dividend yield of 0.92%, which means for every ₹100 invested at the current price of ₹1,207.2, you can expect to receive approximately ₹0.92 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Concord Biotech Ltd's key financial metrics include: P/E Ratio: 37.73, P/B Ratio: N/A, ROE: 11.18%, ROCE: 28.20%, Dividend Yield: 0.92%, EPS: ₹30.89, Book Value: ₹173.27, Debt-to-Equity: 0.00, and Current Ratio: N/A. The company's market cap stands at ₹11,978.03 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Concord Biotech Ltd stock opened at ₹1,203.7 and is currently trading at ₹1,207.2, showing a gain of ₹3.50 (0.29%). The intraday high is ₹1,214 and low is ₹1,188.6. The trading volume stands at 48,879 shares, indicating moderate market participation today.
Concord Biotech Ltd has a Price-to-Earnings (P/E) ratio of 37.73, which means investors are willing to pay ₹37.73 for every ₹1 of earnings. With an EPS of ₹30.89, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Concord Biotech Ltd has a market capitalization of ₹11,978.03 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹1,207.2) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Concord Biotech Ltd has a book value of ₹173.27 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,207.2, which is 596.7% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Concord Biotech Ltd has a Return on Equity (ROE) of 11.18% and Return on Capital Employed (ROCE) of 28.20%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These are moderate returns, suggesting decent operational efficiency. Higher percentages generally indicate better financial performance.
Concord Biotech Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Concord Biotech Ltd has a debt-to-equity ratio of 0.00, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Concord Biotech Ltd has an Earnings Per Share (EPS) of ₹30.89, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,207.2 and P/E ratio of 37.73, investors are paying 37.73 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Concord Biotech Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Concord Biotech Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Concord Biotech Ltd stock, consider: 1) Fundamental Analysis - Review P/E (37.73), ROE (11.18%), debt-to-equity (0.00), and growth rates. 2) Technical Analysis - Check 52-week range (₹1068.60 - ₹2150.40), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1207.20) with book value (₹173.27) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Concord Biotech Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,207.2 is 120620x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Concord Biotech Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1068.60 - ₹2150.40). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.00 indicates leverage. 4) Liquidity Risk - Based on trading volume of 48,879 shares. 5) Valuation Risk - P/E of 37.73 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Concord Biotech Ltd operates in the industry with key metrics: P/E ratio of 37.73, ROE of 11.18%, market cap of ₹11,978.03 crores, and dividend yield of 0.92%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.00), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Concord Biotech Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,207.2, with a 52-week range of ₹1068.60 to ₹2150.40. Based on fundamentals like P/E (37.73), ROE (11.18%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Concord Biotech Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1207.20. 2) Fundamental Deterioration - Declining ROE (currently 11.18%), increasing debt (D/E: 0.00), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Concord Biotech Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.92%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu